Profil
May Han is currently a Partner at Cure Ventures Management LP since 2021.
Prior to this, she worked as a Director at Novartis AG from 2013 to 2021 and as a Director at AVEO Pharmaceuticals, Inc. from 2003 to 2012.
Dr. Han received her undergraduate degree from Peking University in 1990 and her doctorate degree from Yale University in 1996.
Aktive Positionen von May Han
| Unternehmen | Position | Beginn |
|---|---|---|
Cure Ventures Management LP
Cure Ventures Management LP Investment ManagersFinance Cure Ventures invests in companies located in the United States. The firm targets companies operating in the fields of life science and biotechnology sectors. It provides financing for seed and early stage capital requirements. It acts as a lead investor and also makes follow-on investments. | Private Equity Investor | 01.09.2021 |
Ehemalige bekannte Positionen von May Han
| Unternehmen | Position | Ende |
|---|---|---|
| NOVARTIS AG | Direktor/Vorstandsmitglied | 30.09.2021 |
| AVEO PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 30.06.2012 |
Ausbildung von May Han
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Novartis AG
Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Peking University
Peking University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops cancer therapeutics | Health Technology |
Cure Ventures Management LP
Cure Ventures Management LP Investment ManagersFinance Cure Ventures invests in companies located in the United States. The firm targets companies operating in the fields of life science and biotechnology sectors. It provides financing for seed and early stage capital requirements. It acts as a lead investor and also makes follow-on investments. | Finance |
















